Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.795
-0.115 (-3.95%)
Mar 31, 2025, 1:15 PM EDT - Market open
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Matthew Pauls |
Contact Details
Address: 1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047 United States | |
| Phone | 512 614 1848 |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| Employer ID | 84-1318182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls J.D., M.B.A. | Chairman and Chief Executive Officer |
| David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer and Secretary |
| Robert Matthew Lutz M.B.A. | Chief Operating Officer |
| Kate McCabe J.D. | Chief Legal Officer |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Executive Vice President and Head of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 8-K | Current Report |
| Mar 27, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 144 | Filing |